Maria Humeniuk-Arasiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Humeniuk-Arasiewicz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Grażyna Stryjewska-Makuch
Department of Laryngology and Laryngological Oncology, Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University, 40-635 Katowice, Poland
4 shared publications - Marcelina Niemiec-Urbańczyk
Department of Laryngology and Laryngological Oncology, Upper-Silesian Medical Centre, Medical University of Silesia, 40-635 Katowice, Poland
3 shared publications - Joanna Glück
Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, 40-752 Katowice, Poland
2 shared publications Bogdan Kolebacz
Independent Public Research Hospital N° 7 of Silesian Medical University, Upper Silesian Medical Centre, Department of Laryngology and Laryngological Oncology, Katowice, Poland
1 shared publication- Joanna Glück
Department of Internal Diseases, Allergology and Clinical Immunology in Katowice, Medical University of Silesia, 40-752 Katowice, Poland
1 shared publication - Karolina Goroszkiewicz
Department of Laryngology and Laryngological Oncology, Upper-Silesian Medical Centre, Medical University of Silesia, 40-635 Katowice, Poland
1 shared publication
Latest Publications
- Open Access
Long-Term Postoperative Patient-Reported Quality of Life After Endoscopic Surgery for Sinonasal Inverted Papilloma: A Longitudinal Cohort Study
Background and Objectives: Sinonasal inverted papilloma (IP) is a benign yet locally aggressive tumour associated with a clinically relevant risk of recurrence and malignant transformation. While surgical outcomes are well documented, data on long-term patient-reported quality of life (QoL) remain limited and are often based on short-term or single time-point assessments using disease-specific instruments alone. Materials and Methods: We conducted a single-centre observational cohort study of adults with histologically confirmed IP treated endoscopically. Patients were followed in a university-affiliated otorhinolaryngology outpatient clinic and completed the Sino-Nasal Outcome Test-22 (SNOT-22) at each visit; from 2022 onwards, the generic WHOQOL-BREF questionnaire was additionally administered. Longitudinal SNOT-22 trajectories were analysed using generalised additive models and linear mixed-effects models. In a subgroup of patients, retrospectively recalled preoperative SNOT-22 and WHOQOL-BREF scores were used only for exploratory paired pre–post comparisons. Results: Sixty-nine patients were included. Mean follow-up was 63.1 ± 27.8 months, and recurrence occurred in 21 of 69 patients (30%). A total of 461 postoperative SNOT-22 assessments with complete follow-up time data were included in the longitudinal analysis, with a median of six assessments per patient. Mean postoperative SNOT-22 score was 25.4 ± 19.8, and longitudinal postoperative trajectories showed a largely stable course over time. In the paired exploratory subgroup (n = 34), retrospectively recalled preoperative SNOT-22 scores were higher than postoperative scores, although these exploratory findings should be interpreted cautiously because baseline PROMs were not collected prospectively. Exploratory paired comparisons of WHOQOL-BREF showed higher postoperative scores in the physical, psychological and environmental domains. Conclusions: Patients with sinonasal IP treated endoscopically can achieve favourable and largely stable long-term disease-specific and generic QoL. No single baseline clinical factor showed a clear association with postoperative SNOT-22 scores in the longitudinal models. Combining disease-specific and generic patient-reported outcome measures with longitudinal modelling may support more informed postoperative counselling in this rare, recurrent condition, while structured surveillance remains essential.
Open AccessLong-Term Postoperative Patient-Reported Quality of Life After Endoscopic Surgery for Sinonasal Inverted Papilloma: A Longitudinal Cohort Study
Background and Objectives: Sinonasal inverted papilloma (IP) is a benign yet locally aggressive tumour associated with a clinically relevant risk of recurrence and malignant transformation. While surgical outcomes are well documented, data on long-term patient-reported quality of life (QoL) remain limited and are often based on short-term or single time-point assessments using disease-specific instruments alone. Materials and Methods: We conducted a single-centre observational cohort study of adults with histologically confirmed IP treated endoscopically. Patients were followed in a university-affiliated otorhinolaryngology outpatient clinic and completed the Sino-Nasal Outcome Test-22 (SNOT-22) at each visit; from 2022 onwards, the generic WHOQOL-BREF questionnaire was additionally administered. Longitudinal SNOT-22 trajectories were analysed using generalised additive models and linear mixed-effects models. In a subgroup of patients, retrospectively recalled preoperative SNOT-22 and WHOQOL-BREF scores were used only for exploratory paired pre–post comparisons. Results: Sixty-nine patients were included. Mean follow-up was 63.1 ± 27.8 months, and recurrence occurred in 21 of 69 patients (30%). A total of 461 postoperative SNOT-22 assessments with complete follow-up time data were included in the longitudinal analysis, with a median of six assessments per patient. Mean postoperative SNOT-22 score was 25.4 ± 19.8, and longitudinal postoperative trajectories showed a largely stable course over time. In the paired exploratory subgroup (n = 34), retrospectively recalled preoperative SNOT-22 scores were higher than postoperative scores, although these exploratory findings should be interpreted cautiously because baseline PROMs were not collected prospectively. Exploratory paired comparisons of WHOQOL-BREF showed higher postoperative scores in the physical, psychological and environmental domains. Conclusions: Patients with sinonasal IP treated endoscopically can achieve favourable and largely stable long-term disease-specific and generic QoL. No single baseline clinical factor showed a clear association with postoperative SNOT-22 scores in the longitudinal models. Combining disease-specific and generic patient-reported outcome measures with longitudinal modelling may support more informed postoperative counselling in this rare, recurrent condition, while structured surveillance remains essential.
- 25 November 2025
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 79 (6) , 1-8
Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: Case Analysis and Proposal of a Qualification Scheme
Introduction: Primary chronic rhinosinusitis with nasal polyps (CRSwNP) is a severe, often uncontrolled disease whose pathomechanism involves type 2 inflammation (T2). Biologic drugs targeting interleukin 4 and 13 (dupilumab) receptors and blocking interleukin 5 (mepolizumab) have been approved for the treatment of the T2 endotype.Aim: Presentation of the authors’ suggestions that guided the choice of an appropriate biologic agent when initiating qualification for the treatment of patients with CRSwNP, based on the authors’ experience and data from the literature related to biologic therapy.Materials and methods: Patients with CRSwNP were qualified for biological treatment in accordance with the EPOS (European Position Paper on Rhinosinusitis) guidelines and the criteria of the B.156 drug program. The choice of an appropriate biologic was based on medical history data, such as the level of asthma control, presence of allergies, and the occurrence of N-ERD (nonsteroidal anti-inflammatory drug–exacerbated respiratory disease), as well as biomarker results: total IgE concentration and absolute blood eosinophil count.Results: The study included 43 patients (23 treated with mepolizumab, 20 treated with dupilumab). Groups of patients were comparable in terms of age, sex, number of sinonasal surgeries, prevalence of asthma, NSAIDs (non-steroidal anti-inflammatory drugs) sensitivity, atopy and initial SNOT-22 (Sinonasal Outcome Test-22), VAS (Visual Analog Scale), NPS (Nasal Polyp Score), and L-K score (Lund-Kennedy score). Eosinophilia total range was 250–1000 cells/microL. Baseline peripheral blood eosinophil count was significantly higher in the mepolizumab-treated group. In the dupilumab-treated group, increases in eosinophil counts up to 3500 cells/μl were observed during therapy; however, no patient developed clinical features of hypereosinophilic syndrome.Conclusions: When selecting a biologic drug for the treatment of CRSwNP, it is recommended to consider not only the values of available biomarkers, but also the degree of asthma control, the cumulative dose of oral corticosteroids (OCSs), the patient’s age, and treatment convenience for the patient.
- 25 November 2025
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 79 (6) , 1-8
Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: Case Analysis and Proposal of a Qualification Scheme
Introduction: Primary chronic rhinosinusitis with nasal polyps (CRSwNP) is a severe, often uncontrolled disease whose pathomechanism involves type 2 inflammation (T2). Biologic drugs targeting interleukin 4 and 13 (dupilumab) receptors and blocking interleukin 5 (mepolizumab) have been approved for the treatment of the T2 endotype.Aim: Presentation of the authors’ suggestions that guided the choice of an appropriate biologic agent when initiating qualification for the treatment of patients with CRSwNP, based on the authors’ experience and data from the literature related to biologic therapy.Materials and methods: Patients with CRSwNP were qualified for biological treatment in accordance with the EPOS (European Position Paper on Rhinosinusitis) guidelines and the criteria of the B.156 drug program. The choice of an appropriate biologic was based on medical history data, such as the level of asthma control, presence of allergies, and the occurrence of N-ERD (nonsteroidal anti-inflammatory drug–exacerbated respiratory disease), as well as biomarker results: total IgE concentration and absolute blood eosinophil count.Results: The study included 43 patients (23 treated with mepolizumab, 20 treated with dupilumab). Groups of patients were comparable in terms of age, sex, number of sinonasal surgeries, prevalence of asthma, NSAIDs (non-steroidal anti-inflammatory drugs) sensitivity, atopy and initial SNOT-22 (Sinonasal Outcome Test-22), VAS (Visual Analog Scale), NPS (Nasal Polyp Score), and L-K score (Lund-Kennedy score). Eosinophilia total range was 250–1000 cells/microL. Baseline peripheral blood eosinophil count was significantly higher in the mepolizumab-treated group. In the dupilumab-treated group, increases in eosinophil counts up to 3500 cells/μl were observed during therapy; however, no patient developed clinical features of hypereosinophilic syndrome.Conclusions: When selecting a biologic drug for the treatment of CRSwNP, it is recommended to consider not only the values of available biomarkers, but also the degree of asthma control, the cumulative dose of oral corticosteroids (OCSs), the patient’s age, and treatment convenience for the patient.
- Open Access
- 17 July 2017
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 84 (2) , 232-239
Giant fronto-ethmoidal osteoma – selection of an optimal surgical procedure
- 17 July 2017
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 84 (2) , 232-239
Open AccessGiant fronto-ethmoidal osteoma – selection of an optimal surgical procedure